Sex steroid hormone metabolism in relation to risk of aggressive prostate cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 23, Issue 11, 2014, Pages 2374-2382

  Black, Amanda ^a   Pinsky, Paul F ^a   Grubb, Robert L ^b   Falk, Roni T ^a   Hsing, Ann W ^c,g   Chu, Lisa ^c,g   Meyer, Tamra ^d   Veenstra, Timothy D ^e   Xu, Xia ^f   Yu, Kai ^a   Ziegler, Regina G ^a   Brinton, Louise A ^a   Hoover, Robert N ^a   Cook, Michael B ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c CANCER PREVENTION INSTITUTE OF CALIFORNIA   (United States)

^d Pharmacovigilance Center   (United States)

^e C2N Diagnostics   (United States)

^f FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^g STANFORD CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN; ESTRONE; SEX HORMONE; TESTOSTERONE;

ADULT; AGED; ARTICLE; CANCER STAGING; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; ESTRADIOL BLOOD LEVEL; ESTRONE BLOOD LEVEL; HUMAN; HYDROXYLATION; MAJOR CLINICAL STUDY; MALE; METABOLITE; MIDDLE AGED; PROSTATE CANCER; RISK ASSESSMENT; SEX DIFFERENCE; STEROID METABOLISM; TANDEM MASS SPECTROMETRY; TESTOSTERONE BLOOD LEVEL; BLOOD; CANCER GRADING; PATHOLOGY; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

AGED; CASE-CONTROL STUDIES; ESTRADIOL; ESTROGENS; ESTRONE; GONADAL STEROID HORMONES; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TESTOSTERONE;

EID: 84920189157     PISSN: 10559965     EISSN: 15387755     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-14-0700     Document Type: Article

References (37)

1. RoddamAW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008;100:170-83.
2. Nelles JL, Hu WY, Prins GS. Estrogen action and prostate cancer. Expert Rev Endocrinol Metab 2011;6:437-51.
3. Bosland MC. A perspective on the role of estrogen in hormoneinduced prostate carcinogenesis. Cancer Lett 2013;334:28-33.
4. Daniels NA, Nielson CM, Hoffman AR, Bauer DC. Sex hormones and the risk of incident prostate cancer. Urology 2010;76:1034-40.
5. Chen C, Weiss NS, Stanczyk FZ, Lewis SK, DiTommaso D, Etzioni R, et al. Endogenous sex hormones and prostate cancer risk: a casecontrol study nested within the Carotene and Retinol Efficacy Trial. Cancer Epidemiol Biomarkers Prev 2003;12:1410-6.
6. Dorgan JF, Albanes D, Virtamo J, Heinonen OP, Chandler DW, Galmarini M, et al. Relationships of serum androgens and estrogens to prostate cancer risk: results from a prospective study in Finland. Cancer Epidemiol Biomarkers Prev 1998;7:1069-74.
7. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1996;88:1118-26.
8. Kristal AR, Till C, Tangen CM, Goodman PJ, Neuhouser ML, Stanczyk FZ, et al. Associations of serum sex steroid hormone and 5alpha-androstane- 3alpha,17beta-diol glucuronide concentrations with prostate cancer risk among men treated with finasteride. Cancer Epidemiol Biomarkers Prev 2012;21:1823-32.
9. Yao S, Till C, Kristal AR, Goodman PJ, Hsing AW, Tangen CM, et al. Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial: a nested case-control study. Cancer Causes Control 2011;22:1121-31.
10. Ziegler RG, Faupel-Badger JM, Sue LY, Fuhrman BJ, Falk RT, Boyd- Morin J, et al. A new approach to measuring estrogen exposure and metabolism in epidemiologic studies. J Steroid Biochem Mol Biol 2010;121:538-45.
11. Xu X, Roman JM, Issaq HJ, Keefer LK, Veenstra TD, Ziegler RG. Quantitative measurement of endogenous estrogens and estrogen metabolites in human serum by liquid chromatography-tandem mass spectrometry. Anal Chem 2007;79:7813-21.
12. Fuhrman BJ, Schairer C, Gail MH, Boyd-Morin J, Xu X, Sue LY, et al. Estrogen metabolism and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 2012;104:326-39.
13. Prorok PC, Andriole GL, Bresalier RS, Buys SS, Chia D, Crawford ED, et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 2000;21(6 Suppl):273S-309S.
14. Hayes RB, Reding D, Kopp W, Subar AF, Bhat N, Rothman N, et al. Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials 2000;21(6 Suppl):349S-55S.
15. Weiss JM, Huang WY, Rinaldi S, Fears TR, Chatterjee N, Hsing AW, et al. Endogenous sex hormones and the risk of prostate cancer: a prospective study. Int J Cancer 2008;122:2345-50.
16. Gulati R, Inoue LY, Gore JL, Katcher J, Etzioni R. Individualized estimates of overdiagnosis in screen-detected prostate cancer. J Natl Cancer Inst 2014;106:djt367.
17. Hsing AW, Stanczyk FZ, Belanger A, Schroeder P, Chang L, Falk RT, et al. Reproducibility of serum sex steroid assays in men by RIA and mass spectrometry. Cancer Epidemiol Biomarkers Prev 2007;16: 1004-8.
18. Glantz GM. Cirrhosis and carcinoma of the prostate gland. J Urol 1964;91:291-3.
19. Leav I, Merk FB, Kwan PW, Ho SM. Androgen-supported estrogenenhanced epithelial proliferation in the prostates of intact Noble rats. Prostate 1989;15:23-40.
20. Nguewa PA, Calvo A. Use of transgenic mice as models for prostate cancer chemoprevention. Curr Mol Med 2010;10:705-18.
21. Ricke WA, Ishii K, Ricke EA, Simko J, Wang Y, Hayward SW, et al. Steroid hormones stimulate human prostate cancer progression and metastasis. Int J Cancer 2006;118:2123-31.
22. Rohrmann S, Nelson WG, Rifai N, Brown TR, Dobs A, Kanarek N, et al. Serum estrogen, but not testosterone, levels differ between black and white men in a nationally representative sample of Americans. J Clin Endocrinol Metab 2007;92:2519-25.
23. Swerdlow AJ, Schoemaker MJ, Higgins CD, Wright AF, Jacobs PA. Cancer incidence and mortality in men with Klinefelter syndrome: a cohort study. J Natl Cancer Inst 2005;97:1204-10.
24. Yan L, Spitznagel EL. Soy consumption and prostate cancer risk in men: a revisit of a meta-analysis. Am J Clin Nutr 2009;89:1155-63.
25. Platz EA, Giovannucci E. The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer. J Steroid Biochem Mol Biol 2004;92:237-53.
26. Ellem SJ, Schmitt JF, Pedersen JS, Frydenberg M, Risbridger GP. Local aromatase expression in human prostate is altered in malignancy. J Clin Endocrinol Metab 2004;89:2434-41.
27. Cussenot O, Azzouzi AR, Nicolaiew N, Fromont G, Mangin P, Cormier L, et al. Combination of polymorphisms from genes related to estrogen metabolismand risk of prostate cancers: the hidden face of estrogens. J Clin Oncol 2007;25:3596-602.
28. Tsai CJ,Cohn BA, Cirillo PM, Feldman D, Stanczyk FZ, Whittemore AS. Sex steroid hormones in young manhood and the risk of subsequent prostate cancer: a longitudinal study in African-Americans and Caucasians (United States). Cancer Causes Control 2006;17:1237-44.
29. Platz EA, Leitzmann MF, Rifai N, Kantoff PW, Chen YC, Stampfer MJ, et al. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev 2005;14:1262-9.
30. Severi G, Morris HA, MacInnis RJ, English DR, Tilley W, Hopper JL, et al. Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006;15:86-91.
31. Cavalieri E, Frenkel K, Liehr JG, Rogan E, Roy D. Estrogens as endogenous genotoxic agents-DNA adducts and mutations. J Natl Cancer Inst Monogr 2000:75-93.
32. Muti P, Westerlind K, Wu T, Grimaldi T, De Berry J III, Schunemann H, et al. Urinary estrogen metabolites and prostate cancer: a case-control study in the United States. Cancer Causes Control 2002;13:947-55.
33. Yang L, GaikwadNW, Meza J, Cavalieri EL, Muti P, Trock B, et al. Novel biomarkers for risk of prostate cancer: results from a case-control study. Prostate 2009;69:41-8.
34. Barba M, Yang L, Schunemann HJ, Sperati F, Grioni S, Stranges S, et al. Urinary estrogen metabolites and prostate cancer: a case-control study and meta-analysis. J Exp Clin Cancer Res 2009;28:135.
35. Lewis JS, Thomas TJ, Klinge CM, Gallo MA, Thomas T. Regulation of cell cycle and cyclins by 16alpha-hydroxyestrone in MCF-7 breast cancer cells. J Mol Endocrinol 2001;27:293-307.
36. Bradlow HL, Hershcopf RJ, Martucci CP, Fishman J. Estradiol 16 alpha-hydroxylation in the mouse correlates with mammary tumor incidence and presence of murine mammary tumor virus: a possible model for the hormonal etiology of breast cancer in humans. Proc Natl Acad Sci U S A 1985;82:6295-9.
37. Bradlow HL, Telang NT, Sepkovic DW, Osborne MP. 2-hydroxyestrone: the 'good' estrogen. J Endocrinol 1996;150 Suppl:S259-65.